Phellopterin

Synonyms: 珊瑚菜素
Phellopterin 是一种具有口服活性的呋喃香豆素,也是中枢苯二氮卓类受体的部分激动剂,其通过上调 SIRT1、下调 ICAM-1(减轻慢性炎症并促进糖尿病溃疡愈合)、抑制 STAT3 磷酸化(缓解特应性皮炎)、调节 Akt/PKC 通路(降低 TNF-α 诱导的 VCAM-1 表达并阻断单核细胞粘附)、抑制 TLR4/NF-κB 通路和巨噬细胞 M2 极化(缓解结肠炎相关癌症)发挥抗炎作用,并通过抑制 PU.1/CLEC5A/PI3K-AKT 反馈环路诱导细胞周期阻滞、细胞凋亡(apoptosis)和 DNA 损伤,从而抑制卵巢癌的进展,还可通过促进脂肪细胞分化和增加 PPARγ 缓解小鼠糖尿病,并具有抗 HSV-1 活性,可用于抗炎、抗癌(如卵巢癌、结肠癌)、降血糖、抗糖尿病、抗病毒等研究。
产品编号: MS-O27577 纯度: 99.94% CAS No.: 2543-94-4 分子式: C17H16O5 分子量: 300.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Phellopterin 是一种具有口服活性的呋喃香豆素,也是中枢苯二氮卓类受体的部分激动剂,其通过上调 SIRT1、下调 ICAM-1(减轻慢性炎症并促进糖尿病溃疡愈合)、抑制 STAT3 磷酸化(缓解特应性皮炎)、调节 Akt/PKC 通路(降低 TNF-α 诱导的 VCAM-1 表达并阻断单核细胞粘附)、抑制 TLR4/NF-κB 通路和巨噬细胞 M2 极化(缓解结肠炎相关癌症)发挥抗炎作用,并通过抑制 PU.1/CLEC5A/PI3K-AKT 反馈环路诱导细胞周期阻滞、细胞凋亡(apoptosis)和 DNA 损伤,从而抑制卵巢癌的进展,还可通过促进脂肪细胞分化和增加 PPARγ 缓解小鼠糖尿病,并具有抗 HSV-1 活性,可用于抗炎、抗癌(如卵巢癌、结肠癌)、降血糖、抗糖尿病、抗病毒等研究。

生物实验数据

生物活性 Phellopterin is an orally active furanocoumarin and a partial agonist of central benzodiazepine receptors that exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (alleviating chronic inflammation and promoting diabetic ulcer healing), inhibiting STAT3 phosphorylation (relieving atopic dermatitis), modulating the Akt/PKC pathway (reducing TNF-α-induced VCAM-1 expression and blocking monocyte adhesion), and inhibiting the TLR4/NF-κB pathway and macrophage M2 polarization (relieving colitis-associated cancer), inhibits the progression of ovarian cancer by suppressing the PU.1/CLEC5A/PI3K-AKT feedback loop to induce cell cycle arrest, apoptosis, and DNA damage, alleviates diabetes in mice by promoting adipocyte differentiation and increasing PPARγ, and also possesses anti-HSV-1 activity, making it useful for research on anti-inflammation, anti-cancer (such as ovarian cancer and colon cancer), hypoglycemia, anti-diabetes, and anti-virus.
IC50 & Target

PI3K

 

SIRT3

 

PKC

 

PPARγ

 

Akt

 

ERK

 

TLR4

 

体外研究
(In Vitro)

Phellopterin (1-50 μM, 24 h) 在 TNF-α 刺激的人脐静脉内皮细胞 (HUVECs) 中,以剂量依赖性方式显著抑制 VCAM-1 的表达和 Akt 和 PKC 的磷酸化,且通过调节 VCAM-1 的表达有效抑制了单核细胞与 TNF-α 刺激的内皮细胞 (ECs) 的粘附。
Phellopterin (1-25 μM, 24 h) 在 HaCaT 细胞中上调 SIRT1 表达,下调 ICAM-1 表达,从而逆转 IFN-γ 导致的增殖抑制。
Phellopterin (1-16 μM, 24 h) 抑制IL-4诱导的 STAT3 激活,从而抑制 STAT3 介导的 HaCaT 细胞中 TSLP 和 IL-33 的转录。
Phellopterin (1-100 μg/mL, 48 h) 对 OV90 和 SKOV3 细胞的 IC50 分别为18.67和27.75 μg/mL。
Phellopterin (25-50 μg/mL) 通过抑制 DNA 复制、阻滞细胞周期 (G0/G1) 和促进凋亡来抑制 OV90 细胞和 SKOV3 细胞的增殖,从而延缓卵巢癌的进展。
Phellopterin (25 μg/mL, 48 h) 使 OV90 细胞和 SKOV3 细胞中的 CLEC5A/PI3K/AKT 信号失活。
Phellopterin (12.5-100 μg/mL) 诱导脂肪细胞分化,并增加过氧化物酶体增殖物激活受体 γ (PPARγ) 的 mRNA表达。
Phellopterin (1-500 μg/mL, 72 h) 在浓度为 7.81 mg/mL 时,对 HSV-1 复制的病毒滴度为 3.01,且对 Vero 细胞具有显著的细胞毒性,其 CC50 值为 14.61 μg/mL。
Phellopterin (40 min) 可抑制 [3H]地西泮和 [3H]Ro 15-1788 与大鼠脑3, -氨基丁酸 A (GABAA) 受体的苯二氮卓位点的体外结合,IC50 值分别为 400 和 680 nM。

Western Blot Analysis

Cell Line: TNF-α-stimulated HUVECs
Concentration: 1, 5, 10 and 50 μM
Incubation Time: 24 h
Result: Did not inhibit TNF-α-induced ICAM-1 expression, whereas it inhibited VCAM-1 expression from 5 μM, and completely suppressed it at 50 μM concentration.
Had no effect on ERK1/2 phosphorylation, whereas they significantly inhibited the phosphorylation of Akt and PKC in dose-dependent manner.

Immunofluorescence

Cell Line: TNF-α-stimulated HUVECs
Concentration: 1, 5, 10 and 50 μM
Incubation Time: 24 h
Result: Showed significant reduction of adherent cells to ECs from 4-fold to 2.5-fold.

Cell Proliferation Assay

Cell Line: TNF-γ-stimulated HaCaT cells
Concentration: 1, 5 and 25 μM
Incubation Time: 24 h
Result: Stimulated HaCaT cell proliferation.
Was unable to restore cell proliferation to normal levels.

Western Blot Analysis

Cell Line: TNF-γ-stimulated HaCaT cells
Concentration: 2, 4, 8 and 16 μM
Incubation Time: 24 h
Result: Suppressed the STAT3-mediated transcription of TSLP and IL-33.

Western Blot Analysis

Cell Line: IL-4-stimulated HaCaT cells
Concentration: 2, 4, 8 and 16 μM
Incubation Time: 24 h
Result: Suppressed the STAT3-mediated expression of TSLP and IL-33.

Western Blot Analysis

Cell Line: OV90 and SKOV3 cells
Concentration: 25 μg/mL
Incubation Time: 48 h
Result: Significantly reduced the protein levels of CLEC5A, p-PI3K, and p-AKT.
Reduced the expression of PU.1 protein.
体内研究
(In Vivo)

Phellopterin (0.6-2.4 mg/kg, i,v., 共 14 天) 通过 SIRT1 下调 ICAM-1 表达,显著加速糖尿病小鼠创面愈合。
Phellopterin (0.5-4.5 mg/kg, 耳部涂抹给药, 一天两次共 10 天) 改善了小鼠特应性皮炎 (AD) 样病变。
Phellopterin (50 mg/kg, i,g., 一周 5 次共 4 周) 抑制小鼠卵巢癌异种移植模型中的癌症生长。
Phellopterin (0.5-2 mg/kg, i,g., 每天一次共 4 周) 显著降低血糖水平,从而预防高脂肪饮食/ Streptozotocin (HFD/STZ) (MS-Q80520) 诱导的小鼠 Ⅱ 型糖尿病。
Phellopterin (0.5-2 mg/kg, i,g.) 通过抑制小鼠巨噬细胞 M2 极化和激活 TLR4/NF-κB 通路,改善结肠炎相关癌症 (CAC) 的症状和炎症反应,抑制结肠癌的发生。

Animal Model: Streptozotocin (STZ) -induced diabetic model established in five-week-old C57BL/6J male mice
Dosage: 0.6, 1.2 and 2.4 mg/kg
Administration: Intravenous injection (i.v.), for 14 days
Result: Seemed to have the greatest effect on wound healing at medium dose.
Promoted diabetic wound healing by accelerating epidermic re-epithelialization.
Downregulated ICAM-1 expression via SIRT1 in mice with diabetic ulcers.
Animal Model: Calcipotriol (MC-903) (MS-Q04527) induced AD like skin model established in male C57BL/6 mice around 8 to 10 weeks of age
Dosage: 0.5, 1.5 and 4.5 mg/kg
Administration: Ear topically spread, twice a day for 10 days
Result: The concentration at 1.5 mg/kg showed the optimal therapeutic effect.
Exhibited significant reduction in epidermal thickness and scales as well as serum IgE levels.
Decreased the infiltrated eosinophils and mast cells.
The protein levels of TSLP and IL-33 in epidermal keratinocytes were decreased.
The expression of IL-4 was remarkably elevated in the AD-like skin lesions, but not significantly changed its expression.
Animal Model: SKOV3 cells induced ovarian cancer xenograft model established in nude mice
Dosage: 50 mg/kg
Administration: Intragastric administration (i.g.), five times a week for 4 weeks
Result: Attenuated cancer growth.
No significant difference in mice body weight and the histopathological changes of the liver and kidney.
Downregulated Ki67 levels in tumor.
Animal Model: High-fat diet/Streptozotocin (HFD/STZ)-induced diabetic established in male ICR strain mice
Dosage: 0.5, 1 and 2 mg/kg
Administration: Intragastric administration (i.g.), once daily for 4 weeks
Result: Decreased total cholesterol from 1154.8 to 630.4 mg/dL.
Dropped triglycerides dropped from 541.6 to 346.7 mg/dL.
Observed no obvious toxic reactions and the organ coefficients were within the normal range.
Animal Model: Azoxymethane (AOM) (MS-I63952)/DSS (Dapsone) (MS-S57992) induced colitis-associated cancer (CAC) model established in C57BL/6 mice
Dosage: 0.5, 1 and 2 mg/kg
Administration: Intragastric administration (i.g.)
Result: Dose-dependently improved the weight loss in mice and increased the length of their colons.
Reduced the rate of tumor formation.
Increased CD4+ and CD8+, and decreased pro-inflammatory factors (IL-6, IL-1β, TNF-α).
Reduced the levels of M2-type markers (such as CD163, CD206, etc.)
Decreased the expression of TLR4 and NF-κB p65.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 300.31
分子式 C17H16O5
CAS No. 2543-94-4
别名 珊瑚菜素

储存&溶解度

体内实验配方
10% DMSO+90% Corn Oil: 2.5 mg/mL (8.32 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (332.99 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.3299 mL16.6495 mL33.2989 mL83.2473 mL
5 mM0.6660 mL3.3299 mL6.6598 mL16.6495 mL
10 mM0.3330 mL1.6649 mL3.3299 mL8.3247 mL
15 mM0.2220 mL1.1100 mL2.2199 mL5.5498 mL
20 mM0.1665 mL0.8325 mL1.6649 mL4.1624 mL
25 mM0.1332 mL0.6660 mL1.3320 mL3.3299 mL
30 mM0.1110 mL0.5550 mL1.1100 mL2.7749 mL
40 mM0.0832 mL0.4162 mL0.8325 mL2.0812 mL
50 mM0.0666 mL0.3330 mL0.6660 mL1.6649 mL
60 mM0.0555 mL0.2775 mL0.5550 mL1.3875 mL
80 mM0.0416 mL0.2081 mL0.4162 mL1.0406 mL
100 mM0.0333 mL0.1665 mL0.3330 mL0.8325 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

珊瑚菜素 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础